Lancet Neurology

Papers
(The H4-Index of Lancet Neurology is 83. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
Increasing diversity in dementia research1555
Correction to Lancet Neurol 2025; 24: 850–651211
The predictive value and clinical use of the neurological pupillary index – Authors' reply1119
Treatment-induced neuropathy of diabetes: an underdiagnosed entity – Authors' reply1066
Lessons and future directions for GBA1-targeting therapies907
Multidisciplinary care for amyotrophic lateral sclerosis647
Resolution of expression of concern—Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study642
Correction to Lancet Neurol 2025; 24: 850–65576
Correction to Lancet Neurol 2024; 23: 168–77569
Correction to Lancet Neurol 2021; 20: 448–59544
Traumatic brain injury research: homogenising heterogeneity483
Safety and efficacy of early versus delayed acetylsalicylic acid after surgery for spontaneous intracerebral haemorrhage in China (E-start): a prospective, multicentre, open-label, blinded-endpoint, r458
Correction to Lancet Neurol 2020; 19: 391–401445
Implications of the KIWE trial for low-income and lower-middle-income countries332
The relevance of social and commercial determinants for neurological health318
Dementia diagnosis in the anti-amyloid era316
Bailout intracranial angioplasty or stenting following thrombectomy for acute large vessel occlusion in China (ANGEL-REBOOT): a multicentre, open-label, blinded-endpoint, randomised controlled trial299
RAB32 mutation in Parkinson's disease299
Clinical descriptors of disease trajectories in patients with traumatic brain injury in the intensive care unit (CENTER-TBI): a multicentre observational cohort study283
Concerns regarding the 2024 revisions of the McDonald criteria for diagnosis of multiple sclerosis282
Anti-CD19 CAR T cells for refractory myasthenia gravis278
Global burden of stroke: dynamic estimates to inform action253
Continuous subcutaneous levodopa–carbidopa infusion for Parkinson's disease245
The gut microbiome, systemic inflammation, and autoimmunity in Parkinson's disease237
Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study237
A biological classification of Huntington's disease: the Integrated Staging System233
Surrogate endpoints for progressive multifocal leukoencephalopathy223
Neuropathology of Alzheimer's disease after anti-amyloid β antibody treatment213
Gene therapy for X-linked myotubular myopathy: the challenges193
Parkinson's disease is a recognisable and useful diagnostic entity187
Diana Cejas187
Aspiring to restore arm and hand function after stroke185
The Genetic Epidemiology of Parkinson's Disease view – Authors' reply180
Albert Kwaku Akpalu176
A chilly tale of dementia171
A study in healing the wounds of trauma165
A nasal CGRP receptor antagonist for acute migraine therapy165
Trials in intracerebral haemorrhage: a path to success?154
Delving into the human mind151
Beyond the modular brain150
Considering the neurological health needs of LGBTQIA people150
A sensitive portrayal of a controversial condition141
Intracranial pressure monitoring with and without brain tissue oxygen pressure monitoring for severe traumatic brain injury in France (OXY-TC): an open-label, randomised controlled superiority trial139
Epilepsy syndromes: an essential piece of the puzzle135
Amyotrophic lateral sclerosis from genotoxins alone?134
Long-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial133
2025 for neuromuscular diseases: a year of multiple advances133
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised contro131
Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): a randomised, statistician-blinded, parallel-arm tri127
Complex regional pain syndrome: advances in epidemiology, pathophysiology, diagnosis, and treatment125
Guiding the future of neurology: our peer-reviewers in 2025124
Miratul Muqit: leading an alliance to decode Parkinson's disease122
Global burden of headache disorders: innovations, disparities, and priorities for action122
From stroke awareness to stroke action awareness121
Correction to Lancet Neurol 2022; 21: 284–94120
Correction to Lancet Neurol 2023; 22: 812–25120
B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases117
The prescription of valproate: risk of harm117
Social connection: a fundamental need for good health117
Safety and efficacy of intra-erythrocyte dexamethasone sodium phosphate in children with ataxia telangiectasia (ATTeST): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial113
Functional or hysterical?113
A health literacy campaign for Parkinson's disease in Africa: a novel campaign to break down language barriers112
Multiple sclerosis in 2022: old players, new insights112
The ATTeST trial in ataxia telangiectasia: some concerns – Authors' response112
New results for risdiplam in spinal muscular atrophy111
Expansion of stenting indications in the USA103
Responsible innovation in neurology102
Jessica Ailani102
Exploring immunomodulation with azathioprine in Parkinson's disease100
α-synuclein seed amplification and its uses in Parkinson's disease99
Supporting young carers across neurological disorders96
A proposal for equity neuroscience96
Changing multiple-sclerosis-induced thoughts and behaviours94
Neurological infections in 2023: surveillance and prevention92
Learning to be an adult with a disability92
Rethinking AI trials in brain health90
Thank you to The Lancet Neurology's peer reviewers in 202588
Correction to Lancet Neurol 2022; 21: 620–3186
Global burden of meningitis: progress, gaps, and priorities85
Effect of blood pressure-lowering agents on microvascular function in people with small vessel diseases (TREAT-SVDs): a multicentre, open-label, randomised, crossover trial85
Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial85
Correction to Lancet Neurol 2024; 23: 110–2285
Cognitive function in people with functional seizures84
Revisiting candesartan: new evidence for an old option in migraine prevention83
Major advances in Parkinson's disease over the past two decades and future research directions83
0.71235203742981